Welcome to our dedicated page for Pieris Pharmaceu news (Ticker: PIRS), a resource for investors and traders seeking the latest updates and insights on Pieris Pharmaceu stock.
Pieris Pharmaceuticals, Inc. (PIRS) delivers innovative biopharmaceutical solutions through its proprietary anticalin protein platform. This dedicated news hub provides investors and industry stakeholders with essential updates on clinical developments, strategic collaborations, and therapeutic advancements.
Track critical updates including clinical trial progress in immuno-oncology and respiratory therapies, partnership announcements with global pharmaceutical leaders, and regulatory milestones for novel anticalin-based treatments. Our curated news collection serves as a centralized resource for understanding PIRS's role in advancing precision-targeted therapeutics.
Discover timely updates on pipeline developments across key therapeutic areas and business strategy implementations. This repository is designed to help users monitor the company's progress in translating innovative protein engineering into clinical-stage assets.
Bookmark this page for streamlined access to Pieris Pharmaceuticals' latest announcements and scientific breakthroughs. Regularly updated to ensure you stay informed about this clinical-stage biotech innovator's evolving landscape.
Pieris Pharmaceuticals announced positive clinical data for cinrebafusp alfa (PRS-343), presented during the AACR annual meeting on April 17, 2023. The Phase 2 study in HER2-positive gastric cancer indicated a 100% unconfirmed objective response rate among the five patients enrolled, showcasing a promising durability profile. The treatment regimen combined cinrebafusp alfa with ramucirumab and paclitaxel and was well-tolerated. All patients achieved a partial clinical response, with three remaining on study. Pieris is exploring various business strategies to continue developing cinrebafusp alfa, including potential partnerships and an immuno-oncology spinout. The company also highlighted ongoing collaborations and forthcoming data read-outs from related bispecific programs.
Pieris Pharmaceuticals (NASDAQ:PIRS) reported its financial results for the fiscal year ending December 31, 2022, alongside updates on its pipeline. The company is advancing clinical programs, including elarekibep for asthma, with data expected mid-2024 due to increased resources from AstraZeneca. PRS-220, targeting idiopathic pulmonary fibrosis, is in Phase 1 studies with results anticipated in H2 2023. Despite a cash decrease to $59.2 million, R&D expenses dropped to $53 million, reflecting cost-effective operations. The net loss narrowed to $33.3 million or $(0.45) per share, down from $45.7 million or $(0.71) per share in 2021.
Pieris Pharmaceuticals (NASDAQ:PIRS) will host its year-end 2022 investor call on March 29, 2023, at 8:00 AM EDT. The call aims to deliver financial results and a corporate update. Interested participants can dial 877-407-8920 for U.S. and Canada or +1 412-902-1010 for international access. A listen-only audio webcast will also be available here. For those unable to attend, a replay will be offered on their website shortly after. Pieris focuses on developing biotherapeutics for respiratory diseases and cancer using its innovative Anticalin® technology.
Pieris Pharmaceuticals (NASDAQ:PIRS) announced a $5 million milestone achieved from Seagen following the dosing of the first patient in a Phase 1 trial of SGN-BB228 (PRS-346), a bispecific antibody-Anticalin molecule. This trial, aimed at assessing safety and tolerability in patients with advanced melanoma and solid tumors, represents a significant step in their collaboration. The study’s results may provide critical clinical insights for future immuno-oncology developments. Pieris retains the option for U.S. co-promotion for one of their partnered programs with Seagen.
Pieris Pharmaceuticals (NASDAQ:PIRS) announced its management presentation at the Evercore ISI HealthCONx Conference on December 1, 2022, at 12:10 PM ET. The conference will focus on the company’s innovative biotherapeutics developed through its proprietary Anticalin technology platform for treating respiratory diseases and cancer. Investors and interested parties can access the presentation via a webcast. Pieris Pharmaceuticals specializes in creating inhalable Anticalin proteins and locally-activated bispecifics, aimed at improving clinical outcomes in patients.
Pieris Pharmaceuticals (NASDAQ:PIRS), a clinical-stage biotechnology firm, will present at the Jefferies London Healthcare Conference on November 15, 2022, at 7:25 AM GMT. The company focuses on developing biotherapeutics using its proprietary Anticalin technology platform for treating respiratory diseases and cancer. A webcast of the presentation will be available here. Pieris combines protein engineering with an understanding of disease drivers to create innovative medicines for improved patient outcomes.
Pieris Pharmaceuticals reported Q3 2022 financial results, highlighting significant advancements in its clinical pipeline. The company continues to enroll patients in its multi-center phase 2a study of elarekibep for asthma, with top-line results expected by Q3 2023. The first subject of the PRS-220 phase 1 study for idiopathic pulmonary fibrosis has been dosed, while the IND for SGN-BB228 has been accepted. Financially, cash reserves are $69.8 million, down from $117.8 million year-over-year, with a net loss of $9.7 million for Q3 2022.
Pieris Pharmaceuticals (NASDAQ:PIRS) announced the initiation of a phase 1 clinical trial for PRS-220, an inhaled Anticalin protein targeting connective tissue growth factor (CTGF) to treat idiopathic pulmonary fibrosis (IPF). The trial aims to assess safety, tolerability, and pharmacokinetics in healthy volunteers. IPF affects over 3 million globally, with a median survival of 3-5 years post-diagnosis. The administration of PRS-220 via inhalation should provide localized, effective inhibition of CTGF compared to systemic methods. Results are expected next year.
